Literature DB >> 30612738

UBQLN4 Represses Homologous Recombination and Is Overexpressed in Aggressive Tumors.

Ron D Jachimowicz1, Filippo Beleggia2, Jörg Isensee3, Bhagya Bhavana Velpula4, Jonas Goergens5, Matias A Bustos6, Markus A Doll7, Anjana Shenoy8, Cintia Checa-Rodriguez9, Janica Lea Wiederstein10, Keren Baranes-Bachar4, Christoph Bartenhagen11, Falk Hertwig12, Nizan Teper4, Tomohiko Nishi6, Anna Schmitt5, Felix Distelmaier13, Hermann-Josef Lüdecke14, Beate Albrecht15, Marcus Krüger16, Björn Schumacher7, Tamar Geiger8, Dave S B Hoon6, Pablo Huertas9, Matthias Fischer11, Tim Hucho3, Martin Peifer17, Yael Ziv18, H Christian Reinhardt19, Dagmar Wieczorek20, Yosef Shiloh21.   

Abstract

Genomic instability can be a hallmark of both human genetic disease and cancer. We identify a deleterious UBQLN4 mutation in families with an autosomal recessive syndrome reminiscent of genome instability disorders. UBQLN4 deficiency leads to increased sensitivity to genotoxic stress and delayed DNA double-strand break (DSB) repair. The proteasomal shuttle factor UBQLN4 is phosphorylated by ATM and interacts with ubiquitylated MRE11 to mediate early steps of homologous recombination-mediated DSB repair (HRR). Loss of UBQLN4 leads to chromatin retention of MRE11, promoting non-physiological HRR activity in vitro and in vivo. Conversely, UBQLN4 overexpression represses HRR and favors non-homologous end joining. Moreover, we find UBQLN4 overexpressed in aggressive tumors. In line with an HRR defect in these tumors, UBQLN4 overexpression is associated with PARP1 inhibitor sensitivity. UBQLN4 therefore curtails HRR activity through removal of MRE11 from damaged chromatin and thus offers a therapeutic window for PARP1 inhibitor treatment in UBQLN4-overexpressing tumors.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  DNA damage; DNA double-strand break repair; UBQLN4 deficiency syndrome; cancer; genome instability syndrome; homologous recombination; non-homologous end joining; proteasomal degradation; targeted cancer therapy; ubiquitin

Mesh:

Substances:

Year:  2019        PMID: 30612738     DOI: 10.1016/j.cell.2018.11.024

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  60 in total

Review 1.  DNA double-strand break repair pathway choice - from basic biology to clinical exploitation.

Authors:  Ron D Jachimowicz; Jonas Goergens; H Christian Reinhardt
Journal:  Cell Cycle       Date:  2019-05-22       Impact factor: 4.534

2.  Ubiquitin-Modulated Phase Separation of Shuttle Proteins: Does Condensate Formation Promote Protein Degradation?

Authors:  Thuy P Dao; Carlos A Castañeda
Journal:  Bioessays       Date:  2020-09-03       Impact factor: 4.345

Review 3.  DNA damage kinase signaling: checkpoint and repair at 30 years.

Authors:  Michael Charles Lanz; Diego Dibitetto; Marcus Bustamante Smolka
Journal:  EMBO J       Date:  2019-08-08       Impact factor: 11.598

4.  Identification of Mutator-Derived lncRNA Signatures of Genomic Instability for Promoting the Clinical Outcome in Hepatocellular Carcinoma.

Authors:  Xiaolong Tang; Yandong Miao; Jiangtao Wang; Teng Cai; Lixia Yang; Denghai Mi
Journal:  Comput Math Methods Med       Date:  2021-11-11       Impact factor: 2.238

Review 5.  Checkpoint Responses to DNA Double-Strand Breaks.

Authors:  David P Waterman; James E Haber; Marcus B Smolka
Journal:  Annu Rev Biochem       Date:  2020-03-16       Impact factor: 23.643

Review 6.  Structure, dynamics and functions of UBQLNs: at the crossroads of protein quality control machinery.

Authors:  Tongyin Zheng; Yiran Yang; Carlos A Castañeda
Journal:  Biochem J       Date:  2020-09-30       Impact factor: 3.857

7.  Identification of core miRNA prognostic markers in patients with laryngeal cancer using bioinformatics analysis.

Authors:  Guan-Jiang Huang; Bei-Bei Yang
Journal:  Eur Arch Otorhinolaryngol       Date:  2020-08-12       Impact factor: 2.503

8.  Phosphoproteomics reveals novel modes of function and inter-relationships among PIKKs in response to genotoxic stress.

Authors:  Sapir Schlam-Babayov; Ariel Bensimon; Michal Harel; Tamar Geiger; Ruedi Aebersold; Yael Ziv; Yosef Shiloh
Journal:  EMBO J       Date:  2020-11-20       Impact factor: 11.598

9.  Identification and validation of a novel eight mutant-derived long non-coding RNAs signature as a prognostic biomarker for genome instability in low-grade glioma.

Authors:  Aierpati Maimaiti; Xixian Wang; Yinan Pei; Nuerbiye Nuermaimaiti; Abudireheman Tuersunniyazi; Yaeraili Abula; Zhaohai Feng; Lei Jiang; Xin Shi; Maimaitijiang Kasimu
Journal:  Aging (Albany NY)       Date:  2021-06-03       Impact factor: 5.682

10.  Gene Instability-Related lncRNA Prognostic Model of Melanoma Patients via Machine Learning Strategy.

Authors:  Kexin Yan; Yutao Wang; Yining Shao; Ting Xiao
Journal:  J Oncol       Date:  2021-05-25       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.